The FDA really gives the CS producers a catch 22. I wanted to include some documentation that indicated that if one is chronically ill then they should start off with small amounts of CS. This would be a warning to prevent one from becoming very sick from a healing crisis. But I can't do that because that says that CS kills pathogens, and then the FDA could come after me. So I am unable to give a real warning to a real possible problem due to the FDA wanting the people to not know that it works..
Go figure. Marshall Thora Rasmussen wrote: > It is my understanding that non drug products cannot make cure claims, so > anything mentioning the actual way to use it would not be allowed. This > letter was trickily written. It actually does not say it is dangerous. It > just says the limitations on labelling. I am unsure on what the US rules > for dosage are, but I think what they are saying is that dosages need to be > clearly marked. In Canada many things will have dosage recommendations at a > level that will not harm anyone, but for those people doing their own > research, they will take however much they want. If necessary, warnings can > also be included to indicate if, for example, a rash or stomache ache occurs > to discontinue use. Here in Canada, there is no way you could possibly > figure out how to use products unless you obtained the information in a > different spot than the bottle. Here, those 2 things cannot legally exist > together. That is why we often see one site with product info that does not > really tell us how much to take and when. The light warning against argyria > looks like just a scare tactic without actually lying. The abuse that is > required to cause it is so way beyond even most radical users, but they just > "gotta" throw that in there. Wouldn't it be interesting to see this type of > warning on every drug, food, and OTC medicine. No one would leave there > house!! We'd all be scared to death!! > > Thora > > -----Original Message----- > From: bob smith [mailto:[email protected]] > Sent: Monday, February 16, 2004 2:33 PM > To: [email protected] > Subject: CS>Emailing: ANS00971 > > I just came across this article. I had never heard of these restrictions on > CS. My understanding was that they did not find it harmful. But there > could be no claims made as to its benefits. Bob Smith > > FDA > TALK PAPER > Food and Drug Administration > U.S. Department of Health and Human Services > Public Health Service 5600 Fishers Lane Rockville, MD 20857 > > FDA Talk Papers are prepared by the Press Office to guide FDA personnel in > responding with consistency and accuracy to questions from the public on > subjects of current interest. Talk Papers are subject to change as more > information becomes available. > > T99-39 Print Media: 301-827-6242 > August 17, 1999 > Consumer Inquiries: 888-INFO-FDA > > FDA ISSUES FINAL RULE ON > OTC DRUG PRODUCTS CONTAINING COLLOIDAL SILVER > The FDA has issued a Final Rule declaring that all over- the-counter (OTC) > drug products containing colloidal silver or silver salts are not recognized > as safe and effective and are misbranded. > Colloidal silver is a suspension of silver particles in a colloidal > (gelatinous) base. In recent years, colloidal silver preparations of unknown > formulation have been appearing in stores. These products are labeled to > treat adults and children for diseases including HIV, AIDS, cancer, > tuberculosis, malaria, lupus, syphilis, scarlet fever, shingles, herpes, > pneumonia, typhoid, tetanus and many others. > According to the Final Rule, a colloidal silver product for any drug use > will first have to be approved by FDA under the new drug application > procedures. The Final rule classifies colloidal silver products as > misbranded because adequate directions cannot be written so that the general > public can use these drugs safely for their intended purposes. They are also > misbranded when their labeling falsely suggests that there is substantial > scientific evidence to establish that the drugs are safe and effective for > their intended uses. > The indiscriminate use of colloidal silver solutions has resulted in cases > of argyria, a permanent blue-gray discoloration of the skin and deep > tissues. > Colloidal silver ingredients and silver salts include silver proteins, mild > silver protein, strong silver protein, silver chloride, and silver iodide. > The dosage form of these colloidal silver products is usually oral, but > product labeling also contains directions for topical and, occasionally, > intravenous use. > In reaching its decision, FDA considered all of the information described in > the proposed rule (October 15, 1996) and submitted by the public in response > to that proposal, the Final Rule becomes effective on September 16, 1999, 30 > days after publication. > #### > > -- > The Silver List is a moderated forum for discussing Colloidal Silver. > > Instructions for unsubscribing are posted at: http://silverlist.org > > To post, address your message to: [email protected] > Silver List archive: http://escribe.com/health/thesilverlist/index.html > > Address Off-Topic messages to: [email protected] > OT Archive: http://escribe.com/health/silverofftopiclist/index.html > > List maintainer: Mike Devour <[email protected]> -- The Silver List is a moderated forum for discussing Colloidal Silver. Instructions for unsubscribing are posted at: http://silverlist.org To post, address your message to: [email protected] Silver List archive: http://escribe.com/health/thesilverlist/index.html Address Off-Topic messages to: [email protected] OT Archive: http://escribe.com/health/silverofftopiclist/index.html List maintainer: Mike Devour <[email protected]>
